Clinical trial · Observational
Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme
Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme Response to Treatment With Bevacizumab for Progressive Disease
NCT01604590CI-TRIAL-00017472completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is for subjects with a diagnosis of a brain tumor called glioblastoma that is being treated with bevacizumab. This study will use a new MRI technique to compare the images of blood vessels and tumor structure to the effectiveness of bevacizumab.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnetic Resonance Imaging (MRI) | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- glioblastoma patients on bevacizumab
- interventionNames
- Radiation: Magnetic Resonance Imaging (MRI)
Primary outcomes (1)
- measure
- MRI to show differences between bevacizumab responses
- timeFrame
- 1 month
- description
- The MRI parameters will help show the differences between bevacizumab-responsive and bevacizumab non-responsive recurrent glioblastoma
Secondary outcomes (1)
- measure
- Progression Free Survival at 3 months
- timeFrame
- 3 months
- description
- The progression of the subject's disease will be evaluated at 3 months.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age between 18 and 80 years of age * Progressive glioblastoma patients who have been planned to receive bevacizumab * Karnofsky Performance Status 50 or above (vd. Appendix A) * Established pathologic diagnosis of glioblastoma * Prior treatment with radiation and chemotherapy * Neuroimaging progression of glioblastoma * Able and willing to provide informed consent (or consent of a guardian) Exclusion Criteria: * Contraindication to MRI * Contraindication to bevacizumab therapy * Concurrent enrollment in other neuroimaging trials * Prior therapy with bevacizumab * Known hypersensitivity to MRI contrast * Females who are nursing or pregnant
References
Publications (0)
Data not yet available
No reference posted for this study.